How Do IT Budgets Really Work: The Suite Spot

The State of the CIO Survey reports that the majority of CIOs are involved in purchasing decisions about IT spend at some level, whether or not they control it directly. However, when a partnership is formed between the leader and IT teams, CIOs are significantly more likely to be involved with approving the solution purchase (71%) and making the final vendor selection (64%) than in companies where IT is viewed as a cost center or service provider.

Powered by RedCircle

 

Removing the fog of acronym war and delivering the value commentary needed to make complex technologies work for businesses, The Suite Spot is a fireside chat with IT leaders about all topics IT and OT, striving to bring clarity to the business value of traditional tech topics. On this segment of The Suite Spot, hosts Carlos VargasPaul Lewis and Howard Holton  take on IT Budgets and chew over how they really work in large and small organizations alike.

“CIOs rarely control how they spend IT money. In other words, it’s rarely their decision on how their budget gets split into certain types of transactions. But they sometimes, and sometimes more often than not, but just sometimes control when they spend money, and that might be monthly or quarterly. Sometimes, the bigger the organization it might in fact be weekly. And what they usually do control, though, is what they’re spending money on. And the reason why is because most (people) outside of IT don’t know what that IT spend is,” Lewis stated. “They wouldn’t know a firewall from a compute device from capacity and storage. They’re just words to them.”

“Ultimately, the budgets are still divided into these buckets,” explained Holt. “You have an operating expense budget—these are things you spend money on but that are not depreciated; they’re not owned assets by the company. Then you have a cap ex budget, and these are assets that are owned by the company and depreciated over time. That’s probably the most valuable thing for people who don’t have any kind of finance background or any serious P&L to understand because those things are handled drastically differently for tax purposes. And thus, the CFO cares a lot on what those two buckets are.”

According to Holt, the IT/CIO relationship in small organizations tends to be tight, which although allows for more influence on how money is spent, but with stricter budgets. In larger organizations, however, you have more freedom of cash and budget. Regardless, shifting funds from one bucket to another is not something that is ever going to be done on the fly in any organization of any kind.

Make Sure to Subscribe to The Suite Spot to Stay Up to Date!

Follow us on social media for the latest updates in B2B!

Image

Latest

vitro
Analyzing the Suppressive TME in In Vitro Based Assays
April 19, 2025

In the rapidly advancing field of cancer immunotherapy, accurately modeling the tumor microenvironment (TME) has become essential to improving the predictive power of preclinical drug testing. As immune-modulating therapies surge forward, with over 4,000 immune modulators in development globally, scientists are refining assay technologies that maintain the complexity of patient-specific tumor biology. In vitro platforms…

Read More
cancer
Targeting T Cells Within the Cancer Immunity Cycle
April 19, 2025

As cancer immunotherapy continues to reshape treatment landscapes, fine-tuning T-cell responses has become a critical frontier. Recent advances in 3D organoid models and high-content imaging are enabling scientists to closely mimic patient-specific tumor environments—unlocking insights into how T cells behave, respond, and falter under immune checkpoint blockade. With over 4,000 immune modulators in clinical…

Read More
cancer Immunity cycle
Advanced In Vitro Technologies to Investigate Therapeutic Impact on the Cancer Immunity Cycle
April 19, 2025

As immunotherapy revolutionizes cancer treatment, the need for physiologically relevant preclinical models becomes more urgent than ever. Despite the success of immune checkpoint inhibitors, a large majority of patients fail to achieve long-lasting responses, prompting researchers to explore more complex and predictive assays. The cancer immunity cycle, first described in 2013, remains a central framework…

Read More
resistance
Inside Oncology Drug Development: Overcoming Resistance with Science
April 19, 2025

In the last two decades, oncology has undergone a transformation with over 300 new cancer therapies approved by the FDA—many offering novel mechanisms of action. Despite these innovations, resistance to treatment remains a critical challenge, with cancer cells evolving or adapting to evade even the most advanced therapeutics. This issue is particularly pressing given that…

Read More